J&J: positive data for lung cancer drug
(CercleFinance.com) - Johnson & Johnson's Janssen Pharmaceutical Companies yesterday announced long-term results from a study of the combination of Rybrevant (amivantamab-vmjw) and lazertinib as first-line treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
These results and additional data were presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.
The estimated progression-free survival rate was 85% at one year, 65% at two years and 51% at three years. The longest duration of ongoing treatment was more than three years (37.2 months) and the longest median duration of response was nearly three years (35.7 months).
Copyright (c) 2023 CercleFinance.com. All rights reserved.
These results and additional data were presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.
The estimated progression-free survival rate was 85% at one year, 65% at two years and 51% at three years. The longest duration of ongoing treatment was more than three years (37.2 months) and the longest median duration of response was nearly three years (35.7 months).
Copyright (c) 2023 CercleFinance.com. All rights reserved.